Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6832395 | 0.92 | CES2 (0.38) | TSHRCYP3A4ALDH1A1CES2PTGS2 | |
| SCHEMBL12231851 | 0.92 | CYP2C19 (0.43) | TSHRCYP3A4ALDH1A1CES2PTGS2 | |
| SCHEMBL4473680 | 0.92 | CYP2C19 (0.43) | TSHRCYP3A4ALDH1A1CES2PTGS2 | |
| SCHEMBL12231848 | 0.88 | ALDH1A1 (0.47) | TSHRALDH1A1CES2MEN1THRB | |
| SCHEMBL13079898 | 0.83 | ALDH1A1 (0.45) | TSHRALDH1A1CES2THRBHTT | |
| SCHEMBL30917919 | 0.81 | CES2 (0.42) | TSHRCES2PTGS2MEN1THRB | |
| SCHEMBL16259206 | 0.81 | CYP2C19 (0.41) | CES2ACHECYP2C19ATMPOLB | |
| SCHEMBL2736682 | 0.80 | — | — | |
| SCHEMBL5596697 | 0.80 | CYP2C19 (0.38) | CES2CYP2C19ATMPOLBBLM | |
| SCHEMBL22278380 | 0.80 | CPB2 (0.39) | CYP3A4CES2CYP2C19ATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553819-B2 | Multivalent inhibitors of serum amyloid P component | THERACARB INC. (CA) | 2009-06-30 | — | — | US | disclosed |
| US-20070042936-A1 | Multivalent inhibitors of serum amyloid p component | THERACARB INC. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070042936-A1 | Multivalent inhibitors of serum amyloid p component | IAPP, APP, PRNP | TSHR 4583/4885CYP3A4 4758/4885ALDH1A1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.